The Upstate Attention Deficit Hyperactivity Disorders Program is a nationally recognized center for the assessment and treatment of ADHD. Children, adolescents, and adults referred to this program for evaluation undergo a comprehensive protocol of behavior rating scales, interviews, and psychological testing, working directly with Dr. Antshel and his staff in all phases of this process.
Kevin Antshel, Phd., Director
PLease note, not accepting new patients
Depression and Anxiety Disorders
Link to PubMed (Opens new window. Close the PubMed window to return to this page.)
Schwartz TL, Masand PS: The Role of Atypical Antipsychotics in the Treatment of Delirium Psychosomatics 43:3;171-174, May-June 2002
Masand PS, Schwartz TL, Alao A: Research Priorities in Electroconvulsive Therapy Archives of Indian Psychiatry. 6(1):176-179 2000 Summer
Schwartz TL: The Use of Tiagabine Augmentation for Treatment Resistant Anxiety Disorders: A Case Series. Psychopharmacology Bulletin 36(2):53-57, Spring 2002
Masand PS, Gupta S, Schwartz TL, Virk S, Lockwood K, Hameed A, King M, Kaplan DS: Paroxetine in Patients with Irritable Bowel Syndrome: A Pilot Open-Label Study. Primary Care Companion J Clin Psychiatry. 4(1):12-16 2002. Presented APA Annual Conference 2001, New Orleans, LA
Schwartz TL, Leso, L, Beale, M, Ahmed, R, Naprawa, S: Modafinil in the Treatment of Depression with Severe Comorbid Medical Illness Psychosomatics 43:336-337, August 2002
Prakash S. Masand; Thomas L. Schwartz; Xiaohong Wang; Daniel J. Kuhles; Sanja Gupta; Bhushan Agharkar; Jacob Manjooran; M. Ahmad Hameed; William Hardoby; Subhdeep Virk; Bradford Frank. Prescribing Conventional Antipsychotics in the Era of Novel Antipsychotics: Informed Consent Issues. Am J Ther 2002 Nov-Dec;9(6):484-7
Masand PS, Gupta S, Schwartz TL: Does a Pre-existing Anxiety Disorder Predict Response to Paroxetine in IBS? Psychosomatics. 43(6):451-5, 2002 Nov
Schwartz TL, Beale M. Psychotropic induced weight gain alleviated with orlistat. Psychopharm Bull 2003; 37(1): 5-8.
Schwartz TL, Jindal S, Virk S, Wade M: Safety and Tolerability of the Antidepressant, Venlafaxine XR, in the Severely Medically and Surgically Ill. Presented at 2002 SUNY Upstate Medical University Research Poster Session Presented APA IPS Annual Conference 2003, Boston, MA (In Press) Psychosomatics
Malhotra K, Schwartz TL, Hameed U: Is Suicidality a Prognostic Indicator for Major Depression in the Primary Care Setting? Presented at 2002 SUNY Upstate Medical University Research Poster Session. Submitted APA Annual Conference 2003, San Francisco, CA. (In Press) The Journal of Postgraduate Medicine
Schwartz TL, Jindal S, Simionescu M, Nihalani N, Azhar N, Tirmazi S, Hussein J: Effectiveness of Orlistat Versus Diet and Exercise for Weight Gain Associated with Antidepressant Use: A Pilot Study. (In Press) Journal of Clinical Psychopharmacology
Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric Medication Induced Obesity: An Epidemiologic Review. (In press) Obesity Reviews
Schwartz TL, Virk S, Nihalani N, et al. Psychiatric Medication Induced Obesity: An Etiologic Review. (In press) Obesity Reviews
Schwartz TL, Azhar N, Hussein J, Jindal S, Hopkins G, Simionescu M, Nihalani N. Modafinal augmentation to reduce fatigue associated with serotonergic antidepressants. Submitted to Journal of Clinical Psychopharmacology
Schwartz TL, Nihalani N, Simionescu M, Hopkins G: The pharmacodynamic history of treating anxiety: A review. Submitted to Current Pharmaceutical Design
Schwartz TL, Nihalani N, Jindal S, et al. Psychiatric Medication Induced Obesity: Treatment Options. Submitted Obesity Reviews
ADHD Medication Management: We currently offer medication management services for children, adolescents, and adults in the ADHD program. Treatment is individualized and collaborative in nature. The patient is actively involved in their care. All adult/adolescent patients are required to undergo baseline labs and maybe an EKG unless they provide proof of the same done recently. This is done to provide the best standard of care and address any underlying medical issues. Medications management focuses on the ADHD symptoms as well as any other co-morbid psychiatric disorder. Certain patients may require additional referrals or consults.
There are currently two psychiatrists on staff, with experience treating children, adolescents, and adults with ADHD. We also have a number of consultants available at our department for specialized areas of behavioral health treatment.
The ADHD program at SUNY upstate conducts research studies on different aspects of attention deficit hyperactivity disorder (ADHD). These studies may create a better understanding of ADHD and how to treat it.
For more information please call 315-464-3188 or email ADHD@upstate.edu. Please provide a phone number that is best to reach you at and information about what you are calling:
Attention Deficit Hyperactivity Disorder (ADHD) Organizations/Websites: Here is a list of organizations that provide information about different aspects of attention deficit hyperactivity disorder (ADHD).
The following is a list of our in-network insurance providers:
Prior to scheduling your appointment your insurance company will be contacted and you will be informed of your specific insurance benefits. Copays, deductibles, and the percentage of the evaluation covered by insurance will vary depending on your specific insurance plan. A comprehensive evaluation will cost approximately $400.00 dollars out of pocket. The cost of therapy sessions vary.